Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Satoshi Takagi has a total of 82 co-authors. Here are the top co-authors by number of shared publications:

  • Akinori Yamauchi

    5 shared publications
  • Ayano Kudo

    Laboratory of Small Animal Surgery, School of Veterinary Medicine, Azabu University, Kanagawa, Japan

    5 shared publications
  • Ayano Kudo

    Laboratory of Small Animal Surgery, School of Veterinary Medicine Azabu University Sagamihara Kanagawa Japan

    5 shared publications
  • Eiichi Kanai

    Laboratory of Small Animal Surgery, School of Veterinary Medicine, Azabu University, Kanagawa, Japan; Azabu University Veterinary Teaching Hospital, School of Veterinary Medicine, Azabu University, Kanagawa, Japan

    4 shared publications
  • Eiichi Kanai

    Laboratory of Small Animal Surgery, School of Veterinary Medicine, Azabu University, Sagamihara, Japan

    3 shared publications
  • Kenji Hosoya

    Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0819, Japan

    3 shared publications

Latest Publications

  • Open Access

    Educational impact of a self-study online anesthesia monitoring simulator among veterinary students: a randomized trial and a before-and-after study

    by Ayano Kudo, Shintaro Kamo, Yuma Harada, Ryo Oshita, Noriko Chiba, Akinori Yamauchi, Satoshi Takagi

    Simulation-based training in veterinary anesthesiology education is increasingly used; however, most simulators are instructor-led and require on-site participation. This randomized trial aimed to evaluate the educational impact of an online veterinary anesthesia simulator for self-directed learning by visualizing dynamic anesthetic changes and monitoring data. A total of 126 fourth-year veterinary students assigned to either a text-based learning (TL) group or a text-plus-simulator learning (TSL) group (63 per group) were included in the analysis. After a 2-week learning period, the students completed a knowledge examination and structured questionnaire. The overall examination scores did not differ between groups; however, the TSL group had a significantly lower proportion of low scores and performed better on questions requiring interpretation of anesthesia monitoring data. The TSL group reported more positive learning experiences, greater motivation, ease of understanding, and self-confidence. A non-randomized before-and-after study compared two academic-year cohorts of fifth-year veterinary students before (2024; n = 154) and after (2025; n = 129) introduction of the simulator. The post-implementation cohort reported significantly less anxiety about anesthesia procedures before feline neutering surgery training. The online anesthesia simulator promoted active learning and improved interpretation of anesthesia monitoring, while its curricular introduction was associated with reduced anxiety before clinical training with live animals. Integrating online simulation with conventional instruction may help bridge theoretical knowledge and practical anesthesia management in veterinary education.

  • Prognostic Significance of Tumour Infiltrating Lymphocytes in Canine Oral Malignant Melanoma Treated With Anti‐Programmed Cell Death Ligand 1 ( PD ‐ L1 ) Antibody Therapy

    by Shintaro Kamo, Naoya Maekawa, Ayano Kudo, Akinori Yamauchi, Sho Yoshimoto, Yuma Harada, Satoru Konnai, Tomohiro Okagawa, Hayato Nakamura, Yumiko Kagawa, et al.

    Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic strategy for canine oral malignant melanoma (OMM). However, only a subset of cases have shown clinical responses. Additionally, predictive biomarkers for the efficacy of ICIs in veterinary medicine are yet to be established. Tumour‐infiltrating lymphocytes (TILs) are predictive biomarkers for ICI therapy in humans. In this study, we aimed to investigate the predictive utility of TILs for canine OMM treated with ICI therapy. Immunohistochemistry was performed on pre‐treatment pathological tissues to detect cells positive for CD3 (pan‐T cell marker), Granzyme B (cytotoxic T lymphocyte or natural killer cell marker) and Foxp3 (regulatory T cell marker). Further, we analysed the infiltration patterns of these cells and their prognostic utility for anti‐programmed cell death ligand 1 (PD‐L1) antibody therapy. There were variances in the infiltration levels of each TIL subset; further, we observed several TIL infiltration patterns in canine OMM. Survival analysis revealed that high infiltration of CD3 + and Granzyme B + cells was significantly associated with prolonged progression‐free survival and overall survival. Furthermore, the immune cell composition ratio, which reflected the balance between cytotoxic and regulatory cells, was significantly associated with survival time. These findings suggest that canine OMM exhibits immunological phenotypes analogous to those observed in human cancers. Taken together, the TIL profile holds significant potential as a prognostic biomarker for canine OMM treated with anti‐PD‐L1 antibody therapy.


  • Open Access

    Indoor VOC Filtration Mitigates Pulmonary Inflammation in Murine Models of Allergic Asthma and LPS‐Induced Acute Lung Injury

    by Kengo Tomita, Chiharu Ohira, Mao Kaneki, Yukiko Ota, Keiichi Yano, Mona Amano, Masaki Nagane, Satoshi Takagi, Tomoki Fukuyama

    Indoor volatile organic compounds (VOCs) are ubiquitous and often within guideline ranges, yet their impact on allergic lung disease and pharmacologic responses remains unclear. We tested whether lowering VOCs attenuates lung inflammation and modifies antihistamine efficacy in murine asthma and acute lung injury (ALI) models, and related these findings to VOC levels in operating veterinary hospitals. BALB/c mice with Dermatophagoides farinae –induced asthma or lipopolysaccharide‐induced ALI were housed in ambient, specific pathogen–free air or in the same air circulated through an activated carbon/HEPA filter that reduced supply‐air VOCs to near their detection limits. Mice with asthma received fexofenadine (20 mg/kg/day, oral) or vehicle (0.5% methylcellulose in water) during allergen challenge. Lung function, histopathology, bronchoalveolar cells, Th2 cytokines, type 2 innate lymphoid cells, and dorsal root ganglion Ca 2+ responses were measured, and total VOCs were quantified by thermal desorption–gas chromatography–mass spectrometry at five veterinary hospitals. VOC filtration significantly reduced lung injury in both models and improved oxygen saturation in animals with ALI. In those with asthma, filtration reduced eosinophilia, Th2 cytokines, type 2 innate lymphoid cells, and lymphocyte activation, and filtration combined with fexofenadine produced the greatest reductions in airway inflammation and the lowest histamine‐evoked Ca 2+ responses in dorsal root ganglion neurons isolated from these animals. VOCs amplified lipopolysaccharide‐induced inflammatory responses in BEAS‐2B cells. Hospital VOC levels ranged from < 50 to > 600 μ g·m −3 , overlapping with or exceeding the low‐level VOC burdens observed in the animal housing experiments. Under the tested experimental conditions, reducing low‐level indoor VOCs was associated with attenuated inflammatory phenotypes in both allergic asthma and ALI models, and with greater reductions in airway inflammation when combined with fexofenadine in the asthma model. These findings warrant further investigation of indoor VOC control as an adjunctive environmental strategy in clinical and veterinary settings, particularly for susceptible hosts.

  • Open Access

    Exploratory, Randomized, Dose-Response Study of the Anti-PD-L1 Antibody HFC-L1/c4G12 in Dogs with Pulmonary Metastatic Oral Malignant Melanoma

    by Kenji Hosoya, Sangho Kim, Ryohei Kinoshita, Naoya Maekawa, Satoru Konnai, Satoshi Takagi, Michihito Tagawa, Yumiko Kagawa, Tatsuya Deguchi, Ryo Owaki, et al.

    Oral malignant melanoma (OMM) is a highly aggressive malignancy in dogs. The development of effective systemic therapies is urgently required to improve the treatment of canine OMM. Immunotherapy using immune checkpoint inhibitors (ICIs) has been investigated in canines following their dramatic success in human cancer treatment; however, there is still a need for extensive veterinary clinical studies to clarify and optimize their clinical benefits. Among the ICIs under development for canine cancer immunotherapy, c4G12 (HFC-L1), a canine chimeric anti-PD-L1 antibody, has shown promising efficacy in dogs with pulmonary metastatic OMM in previous clinical studies. However, the optimal dose of HFC-L1/c4G12 has not yet been determined. To explore the dose–response relationship of HFC-L1, a multicenter, randomized clinical study was conducted using three different doses (2, 5, or 10 mg/kg via intravenous infusion every 2 weeks) to treat dogs with pulmonary metastatic OMM (n = 8–9 per group). The safety profiles were similar among the dose groups, and numerically longer median overall survival was achieved in the higher dose groups (5 and 10 mg/kg) than in the 2 mg/kg group. Although the study was exploratory in nature with a small sample size, 5–10 mg/kg should be considered the preferred dose in future clinical studies using HFC-L1.


  • Open Access

    Exploring the effect of canine cancer-associated fibroblasts on T cell dynamics through the CXCL12/CXCR4 axis modulated by TGF-β1

    by Ayano Kudo, Shintaro Kamo, Akinori Yamauchi, Sho Yoshimoto, Yuma Harada, Eiichi Kanai, Satoshi Takagi

    Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment (TME) that modulate T cell immunity by secreting humoral factors and forming structural barriers. CAFs secrete the chemokine C-X-C motif chemokine ligand 12 (CXCL12), which binds to C-X-C chemokine receptor 4 (CXCR4) on T cells and induces chemotaxis. Transforming growth factor beta 1 (TGF-β1), another humoral factor secreted by CAFs, has been reported to regulate the CXCL12/CXCR4 axis; however, a direct association between them has not been demonstrated in human medicine or veterinary medicine. This study investigated the role of canine CAFs in T cell migration through the CXCL12/CXCR4 axis and the regulatory influence of TGF-β1. CXCL12 and CXCR4 were expressed in the tumor stroma and on T cells, respectively, in dogs with epithelial malignant tumors. Canine CAFs secreted higher levels of CXCL12 and TGF-β1 than normal fibroblasts, and CAF-derived TGF-β1 modulated both CXCL12 secretion by CAFs and CXCR4 expression on T cells. Furthermore, canine CAFs induced T cell migration through the CXCL12/CXCR4 axis. These findings indicate that CAFs may influence T cell migration through the CXCL12/CXCR4 axis under the regulation of TGF-β1 signaling, highlighting their potential role in shaping T cell dynamics within the TME.


  • Peripheral warming for prevention of hypothermia in small dogs during soft tissue surgery: A randomized controlled trial

    by Ayano Kudo, Ren Oboso, Ryo Oshita, Akinori Yamauchi, Shintaro Kamo, Hiromitsu Yoshida, Eiichi Kanai, Satoshi Takagi


  • Open Access

    Negative Influence of Aging on Differentiation and Proliferation of CD8+ T-Cells in Dogs

    by Akinori Yamauchi, Sho Yoshimoto, Ayano Kudo, Satoshi Takagi

    Immunosenescence is an age-related change in the immune system characterized by a reduction in naïve T-cells and an impaired proliferative capacity of CD8+ T-cells in older individuals. Recent research revealed the crucial impact of immunosenescence on the development and control of cancer, and aging is one of the causes that diminish the therapeutic efficacy of cancer immunotherapies targeting CD8+ T-cell activation. Despite dog cancer being defined as an age-related disease, there are few fundamental understandings regarding the relationship between aging and the canine immune system. Therefore, we aimed to elucidate the characteristics of immunosenescence in dogs and analyzed the effects of aging on the differentiation status and proliferation of canine CD8+ T cells using T-cell specific stimulation with anti-canine CD3/CD28 antibody-coated beads and interleukin-2. As a result, we found that older dogs have a lower proliferative capacity of CD8+ T-cells and a reduction in the naïve subset in their peripheral blood. Further analysis showed that older dogs had attenuated proliferation of the effector and central memory subsets. These results indicate the importance of maintaining less differentiated subsets to expand CD8+ T-cells in dogs and provide helpful insight into the development of dog immune therapies that require T-cell expansion ex vivo.


  • Open Access

    Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma

    by Tatsuya Deguchi, Naoya Maekawa, Satoru Konnai, Ryo Owaki, Kenji Hosoya, Keitaro Morishita, Motoji Nakamura, Tomohiro Okagawa, Hiroto Takeuchi, Sangho Kim, et al.

    Although immune checkpoint inhibitors (ICIs), such as the anti-programmed death-ligand 1 (PD-L1) antibody, have been developed for the treatment of canine malignant melanoma, desirable clinical efficacies have not been achieved. Recent studies in humans have suggested that radiation therapy (RT) combined with ICIs induces robust systemic antitumour immunity in patients with cancer. This study retrospectively examined the therapeutic efficacy of combination therapy (hypofractionated RT and anti-PD-L1 antibody [c4G12]) in dogs with pulmonary metastatic oral malignant melanoma. The intrathoracic clinical benefit rate (CBR)/median overall survival (OS) in the no RT (n = 20, free from the effect of RT), previous RT (n = 9, received RT ≤8 weeks prior to the first c4G12 dose), and concurrent RT (n = 10, c4G12 therapy within ±1 week of the first RT fraction) groups were 10%/185 days, 55.6%/283.5 days (p < 0.05 vs. no RT group), and 20%/129 days (p > 0.05 vs. no RT group), respectively. The adverse events were considered to be tolerable in the combination therapy. Thus, hypofractionated RT before the initiation of c4G12 therapy can be an effective approach for enhancing the therapeutic efficacy of immunotherapy, with acceptable safety profiles. Further prospective clinical studies are required to confirm the findings of this study.